Studies were conducted to determine the mechanism of blood pressure- and cholesterol-lowering effects of funoran on rats fed with a saline solution and cholesterol diet. Clofibrate (COIB) was used as a reference hypolipidemic drug. Funoran caused significant reduction of systolic blood pressure (SBP). Funoran and CPIB significantly reduced serum total cholesterol (TC), free cholesterol (FC), triglyceride (TG), LDL-cholesterol (LDL), and atherogenic index (AI) levels in these rats. The increase of sodium, water excretion and sodium-potassium ratio in urine in the funoran group was more significant in the experimental rats than in the control group. Moreover, the ratio of Na and K in serum decreased with the funoran diet. The CPIB diet enhanced cholesterol level in the liver while the funoran diet suppressed the level, but in feces the former diet did not change the cholesterol level while the latter diet increased it. These results suggest that the enhanced ability to excrete sodium in urine by the funoran diet is an important factor for reducing blood pressure and that the antihyperlipidemic effect of funoran was not caused by the mobilization of peripheral cholesterol on the liver, but by the enhanced excretion of cholesterol into feces.